CytomX Therapeutics CTMX Gain (Loss) on Sale of Assets and Asset Impairment Charges
Gain (Loss) on Sale of Assets and Asset Impairment Charges at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges.
The official record: CytomX Therapeutics’s 10-K, filed March 16, 2026, on SEC EDGAR. View the filing →
Ask your AI about CytomX Therapeutics's gain (loss) on sale of assets and asset impairment charges.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CytomX Therapeutics's gain (loss) on sale of assets and asset impairment charges?
- CytomX Therapeutics (CTMX) reported gain (loss) on sale of assets and asset impairment charges of -$100.5K in Q4 2025.
- How has CytomX Therapeutics's gain (loss) on sale of assets and asset impairment charges changed year-over-year?
- CytomX Therapeutics's gain (loss) on sale of assets and asset impairment charges decreased by 279.2% year-over-year, from -$26.5K to -$100.5K.
- What is the long-term trend for CytomX Therapeutics's gain (loss) on sale of assets and asset impairment charges?
- Over 3 years (2022 to 2025), CytomX Therapeutics's gain (loss) on sale of assets and asset impairment charges has grown at a 16.5% compound annual growth rate (CAGR), from -$254K to -$402K.
- What does gain (loss) on sale of assets and asset impairment charges mean?
- This represents the net impact of gains or losses realized from the disposal of assets, combined with any impairment charges recognized when the carrying value of an asset exceeds its fair value. It provides insight into the company's asset management efficiency and the potential obsolescence of its capital base. A significant loss or impairment may indicate a strategic shift or a decline in the value of long-term investments.